Alzheimer's disease is treated using THC (alone, or in combination with melatonin) administered in an ultra-low dose amount sufficient to (i) reduce AB expression; (ii) reduce AB aggregation: (iii) maintain APP expression; (iv) enhance mitochondrial functioning; (v) decrease phosphorylation of GSK3!3 protein; (vi) decrease the expression of GSK3!3 protein; (vii) decrease phosphorylation of Tau protein; and/or (viii) maintain Tau protein expression, in said patient without severe psychological impairments and side effects associated with higher doses of THC.Pharmaceuticals, Neuroscience, Medical
Alzheimer's disease is treated using THC (alone, or in combination with melatonin) administered in an ultra-low dose amount sufficient to (i) reduce A?? protein levels; (ii) reduce A?? aggregation: (iii) maintain A??PP protein levels; (iv) enhance mitochondrial functioning; (v) decrease phosphorylation of GSK-3?? protein; (vi) decrease GSK-3?? protein levels; (vii) decrease phosphorylation of Tau protein; and/or (viii) maintain Tau protein levels, in said patient without severe psychological impairments and side effects associated with higher doses of THC.Pharmaceuticals, Neuroscience, Medical
